Press Release Archive

09.30.2013

ADVIL® BECOMES OFFICIAL PAIN RELIEVER OF THE NATIONAL HOCKEY LEAGUE AND THE 30 TEAM ATHLETIC TRAINERS

09.24.2013

Pfizer Announces Data For XELJANZ® (tofacitinib citrate) In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2013 Annual Meeting

09.13.2013

Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases

09.03.2013

Pfizer Invites Public To Listen to Webcast of Pfizer Discussion at Health Care Conference

09.02.2013

Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease

08.31.2013

New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon

08.29.2013

Pfizer Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial Of Prevenar 13*

07.29.2013

Pfizer Reports Second-Quarter 2013 Results

07.29.2013

Pfizer To Create Separate, Internal, Global Innovative And Value Businesses

07.29.2013

Pfizer Signs New Agreement With UNICEF To Supply A Total Of Up To 740 Million Doses Of Prevenar 13* For The World’s Poorest Countries Through 2025

07.25.2013

CHMP Confirms Prior Opinion Regarding Marketing Authorization In Europe For Pfizer’s XELJANZ® (tofacitinib citrate)

07.24.2013

Pfizer Provides Historical Consolidated Statements of Income with the Animal Health Business (Zoetis) Reported as a Discontinued Operation